Exelixis, Inc. - Common Stock (EXEL)

Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.

Exelixis will have to wait longer than expected to earn approval for a new drug. It's not the end of the world.

Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer

Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year. Speaking at a Wells biotech session, Chief Financial Officer Chris Senner said the company is worki

Exelixis (NASDAQ:EXEL) executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib through multiple late-stage studies. Speaking at a company event, Andrew Peters, Exelixis’ senior vice p

Cabozantinib revenue grew 10%, while zanzalintinib advances toward FDA decision in December.

Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential late-year launch of zanzalintinib in colorectal cancer and advanced a broader development program f

They are riding strong tailwinds that could lift them higher.

Sometimes, little-known stocks are worth buying.

Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.

Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president of strategy, said during a session hosted by RBC Capital Markets. Peters said Exelixis’ guidance

NCR Atleos delivers self-service banking technology and managed services to financial institutions and enterprise clients worldwide.

It's not the most prominent company in its industry, but it is definitely worth a second look.

Exelixis (EXEL) Q1 2026 Earnings Transcript

These companies boast significant upside potential.